The Washington Post, November 25, 2024: This news article quotes NCHR and other experts explaining that Vivek Ramaswamy is a former biotech executive who is very critical of the FDA in ways that reflect his extensive conflicts of interest. If Donald Trump follows Ramaswamy’s advice, Ramaswamy is likely to greatly increase his wealth and patients will be harmed by paying for expensive new medications that do not work.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Trump’s pick for FDA to test ‘due diligence’ of Agency’s science
Bloomberg Law, November 25, 2024: Dr. Marty Makary has been named by Donald Trump to lead the FDA. The Johns Hopkins surgeon has been an outspoken critic of FDA’s relationships with industry and his appointment could shake up the status quo. NCHR and other experts are optimistic that Dr. Makary will encourage the agency to reduce conflicts of interest and hold industry to a higher standard for FDA approval of medical products and food safety.
Read More »A documentary about menopause has ‘misinformation’ and shouldn’t be used to educate docs, critics say
STAT News, November 21, 2024: We joined other experts in criticizing the Federation of State Medical Boards (FSMB) for their documentary on menopause, which includes several inaccurate claims that hormone therapy has health benefits (such as preventing dementia and heart disease) that are not supported by research.
Read More »What Trump’s election win could mean for AI, climate and health
Nature, November 8, 2024: Nature magazine news article on the impact of Trump election includes views regarding health programs. NCHR asks if RFK Jr. stated plans to “reduce corporate greed” will be implemented, given the close ties between the first Trump Administration and the pharmaceutical industry.
Read More »Michelle Tarver faces challenges as new CDRH leader. But patient groups, industry are optimistic.
MedTech Dive, October 31, 2024: Article quotes industry officials and NCHR and other patient and consumer advocates about new CDRH director Michelle Tarver and hopes for greater respect for patients, consumers, and researchers during user fee negotiations and FDA decision-making regarding the safety and effectiveness standards for medical devices.
Read More »